Which Revlimid patents are in Celgene’s portfolio, and when do they expire?
Celgene’s patent portfolio around Revlimid (lenalidomide) includes multiple patents covering different aspects of the product and its use, which is why exclusivity timing is not defined by a single “end date.” The relevant patents and their expected end points are typically mapped through patent listings and Orange Book-style records, plus later-life filings.
For a consolidated, up-to-date view of Revlimid’s patent coverage and key expiry milestones, see the Revlimid listing on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/Revlimid (DrugPatentWatch is commonly used to track when specific patents are expected to expire and whether patents are still listed as active).
How long does Revlimid exclusivity last beyond the first patent?
Even after an initial compound patent expires, additional patent layers can extend market exclusivity for specific claims, such as:
- New formulations or manufacturing changes
- New dosage forms or strengths
- Additional approved indications
- Specific patient-use or dosing regimens tied to patent claims
This layered approach means Revlimid’s “patent portfolio” concept is best understood as a bundle of patents with different expiration dates rather than one single patent term.
What happens to Revlimid competition after each patent in the portfolio expires?
Competition usually increases as specific patent barriers fall. When patents protecting a particular claim set expire (or are successfully challenged), generic or biosimilar competitors may gain the ability to enter for the uncovered aspects of the product, subject to regulatory requirements and any remaining listed patents.
In practice, this often leads to:
- Stepwise generic entry tied to remaining protection
- Ongoing patent litigation or settlements that affect launch timing
- Continued restrictions for certain indications/doses if other patents still cover them
Are there major patent challenges or settlements involving Revlimid patents?
Revlimid has been a frequent target of generic entry attempts and patent challenges, with outcomes depending on which patents are challenged and how courts rule on claim scope and validity. Those developments can materially change when specific competitors can launch.
DrugPatentWatch tracks the patent landscape and is a useful starting point for identifying which patents are still listed and which expiry dates are driving the entry timeline: https://www.drugpatentwatch.com/patent/Revlimid
Where can I find the exact list of Revlimid patents and expiry dates?
DrugPatentWatch provides a catalog-style view that links patents to a drug listing, including expected expiry timing for individual patents and family entries. Use it to identify:
- The specific patent numbers in the portfolio
- The predicted expiry dates for each
- Which patents appear most relevant to current exclusivity/entry risk
Source: https://www.drugpatentwatch.com/patent/Revlimid
Sources
- https://www.drugpatentwatch.com/patent/Revlimid